Enhancing anticancer activity of checkpoint immunotherapy by targeting RAS

Approximately 30% of human cancers harbor a gain‐in‐function mutation in the RAS gene, resulting in constitutive activation of the RAS protein to stimulate downstream signaling, including the RAS‐mitogen activated protein kinase pathway that drives cancer cells to proliferate and metastasize. RAS‐dr...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:MedComm (2020)
Main Authors: Ward, Antonio B., Keeton, Adam B., Chen, Xi, Mattox, Tyler E., Coley, Alex B., Maxuitenko, Yulia Y., Buchsbaum, Donald J., Randall, Troy D., Zhou, Gang, Piazza, Gary A.
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley and Sons Inc. 2020
Assuntos:
Reviews
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7567124/
https://ncbi.nlm.nih.gov/pubmed/33073260
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/mco2.10
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares